BiHC, a T-Cell–Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells

Vogel, 2002, Efficacy and safety of trastuzumab as a single agent in first-line treatment of her2-overexpressing metastatic breast cancer, J Clin Oncol, 20, 719, 10.1200/JCO.2002.20.3.719 Ross, 1998, The her-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy, Oncologist, 3, 237, 10.1634/theoncologist.3-4-237 Scholl, 2001, Targeting her2 in other tumor types, Ann Oncol, 12, S81, 10.1093/annonc/12.suppl_1.S81 Valabrega, 2007, Trastuzumab: Mechanism of action, resistance and future perspectives in her2-overexpressing breast cancer, Ann Oncol, 18, 977, 10.1093/annonc/mdl475 Lameris, 2014, Bispecific antibody platforms for cancer immunotherapy, Crit Rev Oncol Hematol, 92, 153, 10.1016/j.critrevonc.2014.08.003 Chen, 2016, Bispecific antibodies in cancer immunotherapy, Hum Vaccin Immunother, 12, 2491, 10.1080/21645515.2016.1187802 Loffler, 2000, A recombinant bispecific single-chain antibody, cd19 x cd3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated t lymphocytes, Blood, 95, 2098, 10.1182/blood.V95.6.2098 Przepiorka, 2015, Fda approval: Blinatumomab, Clin Cancer Res, 21, 4035, 10.1158/1078-0432.CCR-15-0612 Chelius, 2010, Structural and functional characterization of the trifunctional antibody catumaxomab, MAbs, 2, 309, 10.4161/mabs.2.3.11791 Chen, 2015, A targeted il-15 fusion protein with potent anti-tumor activity, Cancer Biol Ther, 16, 1415, 10.1080/15384047.2015.1071739 Merchant, 1998, An efficient route to human bispecific igg, Nat Biotechnol, 16, 677, 10.1038/nbt0798-677 Ridgway, 1996, 'Knobs-into-holes' engineering of antibody ch3 domains for heavy chain heterodimerization, Protein Eng, 9, 617, 10.1093/protein/9.7.617 Li, 2016, Single domain antibody-based bispecific antibody induces potent specific anti-tumor activity, Cancer Biol Ther, 17, 1231, 10.1080/15384047.2016.1235659 Rozan, 2013, Single-domain antibody-based and linker-free bispecific antibodies targeting fcgammariii induce potent antitumor activity without recruiting regulatory t cells, Mol Cancer Ther, 12, 1481, 10.1158/1535-7163.MCT-12-1012 Shalaby, 1992, Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the her2 protooncogene, J Exp Med, 175, 217, 10.1084/jem.175.1.217 Kwong, 2009, E. Coli expression and purification of fab antibody fragments, Curr Protoc Protein Sci, 10.1002/0471140864.ps0610s55 So, 2013, A high throughput method for enrichment of natural killer cells and lymphocytes and assessment of in vitro cytotoxicity, J Immunol Methods, 394, 40, 10.1016/j.jim.2013.05.001 Munn, 1989, Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated antitumor cytotoxicity not detected by isotope release assays, J Exp Med, 170, 511, 10.1084/jem.170.2.511 Oberst, 2014, Cea/cd3 bispecific antibody medi-565/amg 211 activation of t cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas, MAbs, 6, 1571, 10.4161/19420862.2014.975660 Li, 2016, A single-domain antibody-linked fab bispecific antibody her2-s-fab has potent cytotoxicity against her2-expressing tumor cells, AMB Express, 6, 32, 10.1186/s13568-016-0201-4 Grote, 2012, Bispecific antibody derivatives based on full-length igg formats, Methods Mol Biol, 901, 247, 10.1007/978-1-61779-931-0_16 Spiess, 2015, Alternative molecular formats and therapeutic applications for bispecific antibodies, Mol Immunol, 67, 95, 10.1016/j.molimm.2015.01.003 Schanzer, 2014, A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (egfr) and insulin-like growth factor receptor type i (igf-1r) demonstrating unique molecular properties, J Biol Chem, 289, 18693, 10.1074/jbc.M113.528109 Gunasekaran, 2010, Enhancing antibody fc heterodimer formation through electrostatic steering effects: Applications to bispecific molecules and monovalent igg, J Biol Chem, 285, 19637, 10.1074/jbc.M110.117382